

PEOPLE WITH DIABETES ARE
**2 TIMES AS LIKELY
TO CONTRACT
HEPATITIS B,
AND THERE IS
NO CURE.**

Vaccination is
the only way to
be protected.

FIND OUT MORE INSIDE.

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Please see additional Important Safety Information throughout this brochure and accompanying full Prescribing Information.

HEPLISAV-B®
Hepatitis B Vaccine (Recombinant), Adjuvanted



**WHEN YOU HAVE
DIABETES, YOU ARE**

**2 TIMES
AS LIKELY**

TO BECOME INFECTED
WITH THE **HEPATITIS B
VIRUS (HBV)**

**UP
TO
4 TIMES
AS LIKELY**

TO GET **HBV-RELATED
LIVER CANCER**

**HBV CAN HAVE SERIOUS
CONSEQUENCES**

**UP
TO
50%**

OF LIVER CANCER
CASES ARE
CAUSED BY HBV


15%

OF CIRRHOSIS
DIAGNOSES ARE
CAUSED BY HBV

~5500

**HBV-RELATED
DEATHS OCCUR
EACH YEAR IN
THE US**

Please see additional Important Safety Information throughout this brochure and accompanying full Prescribing Information.



THE RISK IS REAL

**PEOPLE WITH DIABETES FACE
EXTRA RISK BECAUSE:**

Managing the condition can lead to infection through things like glucose monitoring and injectable medications.



They have weakened immune systems.

WHEN YOU HAVE
DIABETES, YOU ARE

**2 TIMES
AS LIKELY**

TO BECOME INFECTED
WITH THE **HEPATITIS B
VIRUS (HBV)**

**UP
TO 4 TIMES
AS LIKELY**

TO GET **HBV-RELATED
LIVER CANCER**

**HBV CAN HAVE SERIOUS
CONSEQUENCES**

**UP
TO 50%**

OF LIVER CANCER
CASES ARE
CAUSED BY HBV

15%

OF CIRRHOSIS
DIAGNOSES ARE
CAUSED BY HBV

~5500

**HBV-RELATED
DEATHS OCCUR
EACH YEAR IN
THE US**

Please see additional Important Safety Information throughout this brochure and accompanying full Prescribing Information.

HOW DO YOU PROTECT YOURSELF FROM HBV?

The only way to protect against HBV is vaccination.

However, traditional 3-dose hepatitis B vaccines take 6 months to complete. With HEPLISAV-B, you can be protected faster and with fewer injections.

HEPLISAV-B

2 DOSES



1 MONTH APART



VS

TRADITIONAL 3-DOSE VACCINE

3 DOSES



IN 6 MONTHS



IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

WITH HEPLISAV-B, PEOPLE WITH DIABETES HAD HIGHER RATES OF PROTECTION

In a clinical trial of 961 patients with diabetes, 2 doses of HEPLISAV-B provided higher rates of protection compared to Engerix-B, a traditional 3-dose vaccine.

HEPLISAV-B



90.0%
OF PATIENTS WERE
PROTECTED

N=640

VS

TRADITIONAL 3-DOSE VACCINE



65.1%
OF PATIENTS WERE
PROTECTED

N=321

HEPLISAV-B®
Hepatitis B Vaccine (Recombinant), Adjuvanted

IMPORTANT SAFETY INFORMATION

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.



**THE ONLY HEPATITIS B
VACCINE FOR ADULTS
THAT PROTECTS WITH**

2 **IN** **1**
DOSES **MONTH**

**IF YOU HAVE DIABETES,
YOU NEED TO BE PROTECTED
AGAINST HBV.**

**TALK TO YOUR PHARMACIST TO
GET YOUR FIRST DOSE TODAY.**

IMPORTANT SAFETY INFORMATION

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see additional Important Safety Information throughout this brochure and accompanying full Prescribing Information.

Engerix-B is a registered trademark of the GSK group of companies.

DYNAVAX

© 2019 Dynavax Technologies Corporation.

All rights reserved.

October 2019

US-19-00-00211